Day Lila

Biotech · Thursday, 19 November 2026

Written by AI agents built on Claude, from the sources they cite, and overseen by Zeemish. How it's made

This day: every beat The day in 12 minutes

Swipe 19 stories

Biogen's tau drug slows Alzheimer's decline by 38% at two years, in a trial that missed its main goal

19 stories 29 sources

Signals on this beat

New Alzheimer's drug ideas tested Building ↑
  • Biogen's tau drug slowed decline by 38% at 2 years, without proof yet. [1]
  • Priavoid's amyloid pill was not significantly better than a dummy at 48 weeks. [6]
  • Bristol Myers Squibb's Cobenfy eased hallucinations in a look with no dummy group. [7]
Drugmakers buying and dropping drugs High →
  • Merck stopped nemtabrutinib, the drug it paid $2.7 billion for ArQule to get. [12]
  • Pfizer will pay China's Starna $330 million upfront for early cell drugs. [14]
  • GSK won a second approval from its $10.6 billion Nuvalent purchase. [11]
Illness that starts years early Building ↑
  • A toxin from some gut E coli can leave mutations in children's colons, MPs heard. [17]
  • The brain's night-time fluid wash is much weaker in older adults, an MIT study found. [19]
  • Sleep and rhythm trouble can come before memory loss in Alzheimer's. [20]
Health claims ahead of proof High →
  • 16 of 50 online health tests claimed to help people live longer, without evidence. [24]
  • Priavoid pointed to a 35.9% result in a chosen group after its trial missed. [6]
  • The FDA called Summit's late extra analysis exploratory only. [16]

The stories

19 on this beat today.

Each story is told in its parts: what happened, the questions that explain it, how it works, who gains and who pays, and the good news. A part appears when the sources give it.

  1. 01

    Biogen's tau drug slows Alzheimer's decline by 38% at two years, in a trial that missed its main goal

    38%

    slower decline on diranersen after 2 years

    up from 26% at 18 months in the same patients [1]

    1.09 points

    gap on the CDR-SB dementia scale at 2 years

    doctors count 1 point as highly meaningful, Biogen says [1]

    14.8%

    of patients on the 60 mg dose who had episodes of confusion

    up from 13.1% in the data shown in July [1]

    What happened

    • Biogen's experimental Alzheimer's drug, diranersen, slowed decline by 38% over 2 years compared with patients who started on a dummy. [2]
    • Biogen released the figures on Tuesday at CTAD, a yearly meeting on Alzheimer's drug trials in Boston. [2]
    • Lawren VandeVrede, who led the trial, called the growing gap "remarkable and clinically meaningful". [2]
    • That 38% is a gap of 1.09 points on a dementia rating scale called the CDR-SB. [1] Doctors count 1 point as highly meaningful, Biogen says. [1]
    • Biogen gave 60 patients 60 mg twice a year, and 115 others a dummy drug. [2]
    • The trial missed its main goal, which was to show bigger doses working better. [2]
    • Higher doses slowed decline less, and caused more episodes of confusion. [1]
    • Analysts at BMO Capital Markets, an investment bank, say the 2-year gain is still numerical, not statistically significant. [2]

    Who is involved

    Alzheimer's leaves 2 marks in the brain: amyloid plaques outside brain cells and tau tangles inside them. [2]

    Diranersen goes after tau, while the approved drugs Leqembi and Kisunla go after amyloid. [3]

    • Diranersen aims at tau
    • Leqembi and Kisunla aim at amyloid
    • Biogen a US drugmaker that sells the amyloid drug Leqembi with Eisai; it is testing diranersen, a tau drug, with partner Ionis
    • Laura Nisenbaum interim science chief at the Alzheimer's Drug Discovery Foundation; says the benefit may build over time
    • BMO Capital Markets and Jefferies investment banks whose analysts follow drugmakers; they disagree on how clean the 2-year comparison is

    How it unfolded

    Leqembi and Kisunla slow Alzheimer's, but they do not stop it. [3] Both carry warnings for brain swelling, which doctors call ARIA. [3]

    Eisai, which sells Leqembi with Biogen, says the damage process "continues after plaque removal". [4]

    At CTAD, drugmakers also showed drugs aimed at tau, at blood flow and even at light and sound. [2]

    Eli Lilly's little-known drug mevidalen failed its phase 2 study in mild and moderate Alzheimer's, Endpoints reports. [5]

    1. May Trial misses its main goal; Biogen still picks phase 3 [2]
    2. July Biogen reports an unprecedented drop in tau at 18 months [3]
    3. Tuesday 2-year data at CTAD: 38% slower decline [2]

    Why it matters

    Alzheimer's is the most common form of dementia, which affects 57 million people worldwide. [26]

    BMO says twice-yearly doses and no brain swelling could give diranersen an edge over amyloid drugs. [1]

    Rival tau drugs from Novartis, Arrowhead and Voyager were also discussed at CTAD. [1]

    Think it through

    1. 1

      Why did the gap keep growing?

      Laura Nisenbaum, science chief at the Alzheimer's Drug Discovery Foundation, says the benefit may build over time. [2]

    2. 2

      Is it better than the approved drugs?

      Not shown: Kisunla's gap was 0.7 points and Leqembi's 0.45, in separate trials. [1] Those ran 76 weeks and 18 months. [1]

    3. 3

      Who gains if tau drugs work?

      Biogen already sells Leqembi, an amyloid drug, with Eisai. [4] Diranersen, made with its partner Ionis, would give Biogen a tau drug too. [2]

    4. 4

      What does it cost patients?

      14.8% of patients on the 60 mg dose had episodes of confusion, up from 13.1% in July's data. [1]

      patients on the 60 mg dose with episodes of confusion
    5. 5

      So who decides if tau drugs reach patients?

      A phase 3 trial, the big final test before approval, now decides, and Biogen plans one. [2] Novartis, Arrowhead and Voyager have tau drugs in testing too. [1]

    How it works

    Molecular biologists call it an antisense drug: a strand that sticks to a gene's message, so cells make less protein.

    As an antisense drug, diranersen is built to lower tau, and Biogen reported an unprecedented drop in tau. [3]

    Seen it before

    Turning a tap down fills the bath more slowly than bailing water out with a cup.

    The truth

    • Why it works on people A figure like 38% or 35.9% sounds like a result, even when the trial it comes from missed its main goal. [1][6]
    • From week 76, the dummy group switched to diranersen. [2] Jefferies, an investment bank, says they had 1 dose at most, so still count as untreated. [2]
    • BMO calls the comparison imperfect, because some of the dummy group had been dosed by week 96. [1]

    What comes next

    Biogen said in May it will take diranersen into a phase 3 trial. [2]

  1. 02

    A German Alzheimer's pill misses its goal

    What happened

    • Priavoid, a German biotech, said its Alzheimer's pill PRI-002 failed its main goal in a 304-patient trial. [6]
    • The mid-stage trial tested 2 doses in people aged 55 to 80 with mild memory problems or mild dementia. [6]
    • On a dementia rating scale at week 48, the pill was not significantly better than a dummy pill. [2]
    • The pill aims to break small toxic clumps of amyloid back into harmless single pieces. [6]
    • In patients who followed the plan closely, decline was 35.9% slower at week 72 on another scale. [6]
    • Brain bleeds or iron deposits hit 8% and 11.7% on the 2 doses, and 5% on the dummy. [6]

    Why it matters

    Priavoid hoped a daily pill could avoid the brain swelling that the approved antibody drugs can cause. [6]

    Think it through

    1. 1

      So is the 35.9% a win?

      No: Priavoid itself calls it an encouraging signal for more study, not proof. [6]

    2. 2

      What does it share with Biogen's drug?

      Like Biogen's tau drug, it missed its main goal and leaned on later signs. [2]

    3. 3

      What would show the pill is doing anything?

      Priavoid says brain scans and blood markers will help show whether the pill works as designed. [6]

    How it works

    Trial statisticians call the patients who followed the plan closely the per-protocol group. [6]

    Priavoid's 35.9% came from its per-protocol group at week 72, while the full trial missed at week 48. [6]

    Seen it before

    A class average counting only pupils who did all the homework looks better than the whole class.

    Why the protein that starts Alzheimer's may not be the one doing the damage

    Neuroscientists' amyloid cascade idea says amyloid builds up first and sets off tau, which then spreads through brain cells and does the killing.

    The twist

    Once a second process takes over an illness, removing the first cause slows it at best. The treatment has to reach the step that is still running.

    The picture

    The leading idea in Alzheimer's research: amyloid builds first, tau follows inside the cells, and decline comes with tau. The order is still being tested.

    Step by step

    1. Amyloid builds up outside brain cells
    2. It sets off tau tangles inside the cells
    3. Tau spreads and brain cells die
    4. Clearing amyloid now slows decline but does not stop it
    5. So drugs are aimed at tau as well

    The same force, elsewhere today

    Where this chain is also running, in today's other stories.

    • A German Alzheimer's pill misses its goal

      Priavoid's pill went after amyloid's small clumps in people whose decline had already begun, and was not significantly better than a dummy at 48 weeks.

    • A gut toxin leads suspects in young bowel cancer

      Colibactin's mutations land in childhood, and the cancer they help start is found decades later, long after the first damage.

    • A rare fever disease's cause rethought

      Killer cells that cannot kill set off a flood of alarm signals, and doctors helped a baby by blocking the alarm, not by fixing the cells.

    Seen it before

    Epidemiology

    once a virus spreads between people, closing the market where it first jumped does not end the outbreak

    Banking

    a run on a bank can go on after the rumour that started it is shown to be false

    Firefighting

    crews fight the spreading fire front, not the match that lit it

    The catch

    The amyloid cascade is still a hypothesis: amyloid drugs given early may still matter, and tau may not be the only driver.

    And the whole of it

    Patients, families, doctors and drugmakers all meet Alzheimer's at a later step than where it began. Nobody yet knows for sure which step is running in which person.

    The truth

    • What is really going on At CTAD, Biogen, Priavoid and Bristol Myers Squibb each led with a strong number from a part of a trial that cannot prove a drug works. [2][6][7]
    • In patients who stayed 72 weeks, the 12% to 18.8% slower decline was also not statistically significant. [2]

    What comes next

    Priavoid plans to present the full results in 2027. [2]

  1. 03

    A schizophrenia drug eases Alzheimer's hallucinations

    What happened

    • Bristol Myers Squibb said its drug Cobenfy eased hallucinations and delusions in people with Alzheimer's. [8]
    • Cobenfy is already approved in the US to treat schizophrenia. [8]
    • In 273 patients who finished 12 weeks, the hallucination score fell by 12 points from 14.4 on average. [8]
    • All the patients knew they had the real drug: this part of the trial had no dummy group. [7]
    • Side effects hit 56.6% of patients, and 5% had serious ones. [8]

    How it unfolded

    Between 30% and 50% of people with Alzheimer's get hallucinations or delusions at some point. [8]

    1. Now open-label look
    2. 2027 results with a dummy group

    Why it matters

    No US-approved drug treats psychosis in Alzheimer's, so doctors borrow other antipsychotics with safety risks for older people. [8]

    Think it through

    1. 1

      Why does BMS need this to work?

      BMS paid $14 billion for Karuna, Cobenfy's maker, in 2023, and sales have struggled. [7] Truist, an investment bank, predicts worldwide Cobenfy sales of $2.6 billion. [7]

    2. 2

      So what does this look actually show?

      BMO analysts say it shows patients can stay on the drug, not that it prevents relapse. [7]

    3. 3

      So what decides if it counts?

      The blinded part of the trial, still sealed, decides whether patients relapse less on the drug. [8]

    How it works

    Trial designers call this a randomised withdrawal: everyone starts on the drug, then some are switched to a dummy. [8]

    In Cobenfy's randomised withdrawal, 12 open weeks come first, then 26 blinded weeks time each relapse. [8]

    Seen it before

    To test if a plant needs its stick, take the stick from half the plants and see which ones fall.

    The truth

    • BMO says that without a dummy group, nobody can separate the drug's effect from symptoms rising and falling. [7]

    What comes next

    Results with a dummy group, which test whether the drug prevents relapse, are due in 2027. [7]

  2. 04

    First drug for Gaucher's brain symptoms

    What happened

    • The FDA approved Infilbray, a daily pill from Sanofi, for the brain symptoms of type 3 Gaucher disease. [9]
    • It is the first treatment for these symptoms, for adults and children weighing at least 15 kg. [9]
    • In type 3, the build-up also reaches the brain, harming balance, speech, memory and thinking. [9]
    • The trial gave 43 patients either the daily pill or the usual enzyme drip for 52 weeks. [9]
    • After 52 weeks, the pill group did better on a combined score of movement and thinking. [9]
    • Side effects include stomach problems and mood changes, and suicidal thoughts have been reported. [9]

    How it unfolded

    Gaucher disease is inherited: a faulty enzyme cannot break down certain fatty substances, so they build up. [9]

    Why it matters

    Families with type 3 Gaucher had no drug for the build-up in the brain, only for the body. [9]

    Think it through

    1. 1

      Why can't the usual drip help the brain?

      The FDA says the pill crosses the blood-brain barrier and reaches the build-up in the brain. [9]

    2. 2

      Did the pill simply replace the drip?

      No: the trial tested patients already steady on the drip, and compared the pill against it. [9]

    How it works

    Pharmacologists call it substrate reduction: rather than fix the broken enzyme, the drug cuts how much waste is made.

    As substrate reduction, Infilbray blocks the enzyme that makes the fatty substance, so less builds up. [9]

    Seen it before

    If a sink drains slowly, turning the tap down stops the overflow without fixing the drain.

    The truth

    • The approval rests on 43 patients, and the pill beat the drip only on a combined score of 2 tests. [9]
    • Nobody knows yet

      What Infilbray will cost families with type 3 Gaucher, and who pays.

      The FDA's announcement of the approval does not say what Sanofi will charge. [9]

    Good news

    • People with type 3 Gaucher disease, whose brains fill with a fatty substance their bodies cannot break down, now have a first approved drug for those brain symptoms, a daily pill.
  3. 05

    GSK's second lung cancer drug from a buyout

    What happened

    • The FDA approved Nelkarmi, a GSK pill, for advanced lung cancer marked by a change in a gene called ALK. [10]
    • It is for patients whose cancer grew again after other ALK drugs, such as Roche's Alecensa. [10]
    • In patients who had taken only Alecensa before, 49% saw their tumours shrink. [10]
    • Of those who responded, 52% were still responding a year later. [10]

    How it unfolded

    Nelkarmi came with GSK's $10.6 billion purchase of Nuvalent, after Jideytro was approved in July. [11]

    1. July Jideytro approved
    2. This week Nelkarmi approved

    Why it matters

    Patients whose cancer outran earlier ALK drugs would otherwise be left with chemotherapy. [10]

    Think it through

    1. 1

      Why did GSK pay $10.6 billion?

      Analysts at Jefferies think Nuvalent's drugs could bring GSK $5 billion to $7 billion a year at their peak. [10]

    2. 2

      Who does it compete with?

      At first it competes with Pfizer's Lorbrena for patients whose cancer came back. [11]

    3. 3

      So where is the bigger prize?

      In newly diagnosed patients, where a trial now pits it against Alecensa, an RBC analyst wrote. [11]

    How it works

    Regulators call it accelerated approval: a drug cleared on an early sign, like shrinking tumours, before proof of longer life.

    Nelkarmi's accelerated approval rests on its 49% response rate, and GSK is running ALKAZAR, a phase 3 trial. [10]

    Seen it before

    A new player picked on a strong trial game still has to prove it over a full season.

    The truth

    • The approval rests on ALKOVE-1, an early phase 1/2 trial that counted how many tumours shrank. [10]
    • Nobody knows yet

      What GSK will charge for Nelkarmi in the US.

      GSK has not revealed a list price, in the first country to approve the drug. [10]

    Good news

    • Lung cancer patients whose tumours outgrew the usual ALK drugs have a new approved pill, Nelkarmi, which shrank tumours in about half of those tested after one earlier drug.
  4. 06

    Merck drops a $2.7 billion blood cancer bet

    What happened

    • Merck stopped all trials of nemtabrutinib, a blood cancer drug, after one suggested its risks may outweigh its benefits. [12]
    • The drug was tested in chronic lymphocytic leukaemia, a blood cancer, against Imbruvica and Calquence. [13]
    • A review confirmed a safety signal in that trial, so Merck stopped all 3 final-stage trials. [13]
    • Merck had already cut the project's value from $2.3 billion to $418 million. [12]
    • Lilly's rival drug Jaypirca sold $585 million in the first 9 months of 2026, up 63%. [13]

    Who is involved

    • Nemtabrutinib Merck's drug
    • Imbruvica and Calquence the drugs it faced

    How it unfolded

    Merck, called MSD outside the US and Canada, bought the drug's maker ArQule for $2.7 billion in 2019. [13]

    Why it matters

    Patients lose a possible new option, while Lilly's Jaypirca and BeOne's market-leading Brukinsa hold the field. [13]

    Think it through

    1. 1

      Who made the call to stop?

      An outside data monitoring committee reviewed the trial and found the risks may outweigh the benefits. [12]

    2. 2

      Why did Merck want this drug?

      It could hit both normal and changed forms of BTK, the enzyme that resistant cancers alter. [13]

    3. 3

      So who comes out ahead?

      Lilly, whose drug of the same newer kind already sells, and BeOne, the market leader. [13]

    How it works

    Trial safety experts call them a data monitoring committee: outsiders who see the results while a trial runs. [12]

    The data monitoring committee for Bellwave-011 saw the risks before the trial ended, and Merck stopped it. [12]

    Seen it before

    A referee can stop a match for safety before the final whistle, whatever the score.

    The truth

    • The stop rests on Bellwave-011 alone: the other 2 trials were ended without results of their own. [13]
    • Nobody knows yet

      What safety problem stopped Merck's nemtabrutinib.

      Merck and the reports describe only a safety signal in one trial, and give no detail of what it was. [12][13]

  5. 07

    Pfizer buys Chinese cell-reprogramming drugs

    What happened

    • Pfizer will pay Starna Therapeutics $330 million upfront to enter the in vivo CAR-T race. [15]
    • Starna could get up to $2.3 billion more if the drugs hit goals, plus a share of sales. [14]
    • Pfizer gets rights outside Greater China to 3 programmes for autoimmune diseases, not yet tested in people. [14]
    • Starna makes RNA medicines meant to reprogram immune cells inside the body. [14]
    • Today's CAR-T drugs take a patient's cells out, change them in a lab and put them back. [14]
    • It is at least Pfizer's 5th major alliance with a Chinese company since early 2025. [14]

    Why it matters

    If it works, people with lupus or multiple sclerosis could skip the cell harvest and the chemotherapy before it. [14]

    Think it through

    1. 1

      Why so little money now?

      Most of the $2.6 billion is paid only if the drugs pass tests, so Pfizer risks $330 million today. [14]

    2. 2

      Who else is racing for this?

      AstraZeneca, AbbVie, Gilead and Bristol Myers bought such firms in the last 2 years. [14] Lilly bought 2 this year. [14]

    3. 3

      So who holds the stronger hand?

      Starna keeps Greater China and its own technology. [14] Pfizer holds options to take more projects and that territory too. [14]

    How it works

    Immunologists call it CAR-T: immune cells given a new grip that locks onto one target, then destroys what it holds.

    Starna's in vivo CAR-T sends RNA instructions into the body, so immune cells are reprogrammed where they are. [14]

    Seen it before

    Sending a recipe to someone's kitchen is quicker than collecting them, cooking for them and driving them home.

    The truth

    • The work is still early, and Novartis and Bristol Myers paused autoimmune CAR-T trials over safety. [14]
  6. 08

    FDA explains why it refused a lung drug

    What happened

    • On Tuesday the FDA published the letter explaining why it rejected ivonescimab, Summit Therapeutics' lung cancer drug. [11]
    • The trial showed tumours held back longer, but patients did not live longer. [16]
    • The FDA said 93% of the trial's tumour-growth events came from patients enrolled in China. [16]
    • The FDA had warned Summit about this in March 2023 and May 2025, the letter says. [16]
    • It also called the benefit modest against extra risks of serious immune side effects. [16]

    Who is involved

    Summit licensed ivonescimab from Akeso, a Chinese company, which already has approval in China. [16]

    • Akeso licensed it to Summit
    • Summit licensed it outside China

    How it unfolded

    1. March 2023 first warning
    2. May 2025 second warning

    Why it matters

    The refusal has raised doubts about rival drugs of the same kind from Pfizer, Merck and others. [16]

    Think it through

    1. 1

      Why does it matter where patients were?

      The FDA could not say the result applied to US patients, with so few enrolled outside China. [16]

    2. 2

      Did the late extra data help?

      No: Summit sent a new analysis in September, and the FDA called it exploratory only. [16]

    3. 3

      So what does Summit have to do now?

      Summit must run a new trial showing a real benefit, such as longer life. [16] A Leerink analyst says simply reapplying is unlikely to change the answer. [11]

    How it works

    Cancer trialists separate two measures: how long tumours are held back, and how long patients live, called overall survival.

    Ivonescimab held tumours back longer but showed no gain in overall survival, so the FDA judged it modest. [16]

    Seen it before

    A team that holds off a goal for longer can still lose the match.

    The truth

    • What is really going on The FDA's letter to Summit, published the same week, asked for proof that patients live longer, in patients like those who will use the drug. [16]
    • Follow-up stopped earlier for patients in China, where trial sites closed during 2025, the letter says. [16]

    What comes next

    The FDA wants a new trial across several regions, and suggests Summit meet it first. [16]

  7. 09

    A gut toxin leads suspects in young bowel cancer

    What happened

    • A toxin from some gut E coli is the leading suspect in rising bowel cancer in under-50s, MPs heard. [17]
    • Scientists told a committee of British MPs about the toxin, called colibactin. [17]
    • Early-onset bowel cancer cases have doubled in many countries in the past 20 years. [17]
    • Known risks like obesity, smoking and alcohol explain only about half of cases, Oxford's Karl Smith-Byrne said. [17]
    • Mutations the toxin leaves were 3 times more common in tumours of under-40s than over-70s. [17]
    • By age 10, some affected children carry as many mutations as a 50-year-old, Sanger Institute work showed. [17]

    Who is involved

    • UK MPs' science committee heard the evidence

    How it unfolded

    In the US, the overall bowel cancer rate rose in 2023, the first rise in more than 20 years. [18]

    Why it matters

    Helen Coleman of Queen's University Belfast said the exposure is likely in early childhood, possibly before birth. [17]

    Think it through

    1. 1

      Why would young people suddenly get it?

      Imperial's Elio Riboli said colibactin is found mostly in people born after 1960, so E coli may have changed. [17]

    2. 2

      Is it proven to cause the cancer?

      Not yet: more work is needed to show colibactin actually drives the cancer. [17]

    3. 3

      So what can be done while it is studied?

      Riboli said about 60% of cancers now occurring could be prevented with what is already known. [17]

      60%of cancers now occurring could be prevented, Riboli says

    How it works

    Cancer geneticists call it a mutational signature: a cause leaves a pattern of DNA damage, which can be read later.

    Colibactin's signature, its hallmark mutations, shows up 3 times more often in tumours of people under 40. [17]

    Seen it before

    A boot print in the mud names the boot long after the walker has gone.

    The idea, in story 02: Why the protein that starts Alzheimer's may not be the one doing the damage →

    The truth

    • Coleman called colibactin the first new clue in quite some time, but its role is still under investigation. [17]
  8. 10

    Ageing weakens the brain's night-time wash

    What happened

    • MIT researchers found the fluid waves that wash waste from the brain in deep sleep are weaker in older adults. [19]
    • The fluid is cerebrospinal fluid, which moves around the brain and carries waste away. [19]
    • Volunteers aged 18 to 39 and 60 to 84 fell asleep in MRI scanners while the team measured the fluid. [19]
    • Older people's fluid waves were much smaller, and less time asleep did not explain it. [19]
    • Their blood vessels also responded less when busy brain areas needed more blood. [19]
    • The study appeared in the journal Nature Aging. [19]

    Why it matters

    Poor sleep is already linked to dementia, so researchers ask whether a weaker wash adds to that risk. [19]

    Think it through

    1. 1

      What weakens the wash?

      Weaker blood-vessel responses explained much of the drop, but not all of it. [19]

    2. 2

      Does this mean it causes Alzheimer's?

      Not shown: the team now wants to test whether weaker waves predict who will decline. [19]

    How it works

    Neuroscientists call it neurovascular coupling: when a brain area works harder, its blood vessels widen to feed it.

    In older volunteers, neurovascular coupling was weaker: a flickering checkerboard raised brain activity but much less blood flow. [19]

    Seen it before

    A dishwasher with weak water pressure runs the full cycle and still leaves plates dirty.

    The truth

    • Each volunteer had 1 session of about 2 hours, so the study compares 2 age groups rather than following anyone. [19]
  9. 11

    An atlas of the ageing hypothalamus

    What happened

    • Researchers led by the Buck Institute mapped how the hypothalamus changes in ageing and Alzheimer's, in Nature. [20]
    • The hypothalamus, at the base of the brain, runs sleep, daily rhythms, appetite and stress hormones. [20]
    • The team measured 13 parts of the hypothalamus in brain scans from 458 living adults. [20]
    • They also read the active genes in about 614,000 cells from donated brains. [20]
    • The lateral hypothalamus shrank with age, while the body-clock region and others grew. [20]
    • They made the atlas, HypoAD, free for other scientists to use. [20]

    How it unfolded

    Sleep trouble and lost daily rhythms can appear in Alzheimer's before memory is affected. [20]

    1. First sleep and rhythm trouble
    2. Later memory affected

    Why it matters

    It points research at the brain region behind the sleep and appetite changes families often report. [20]

    Think it through

    1. 1

      Did Alzheimer's itself shrink these parts?

      Not clearly: differences tied to Alzheimer's were modest and not statistically significant. [20]

    2. 2

      What did the genes point to?

      Inflammation and body-clock genes best told Alzheimer's cells from healthy ones. [20]

    How it works

    Biologists call it single-cell sequencing: reading which genes are switched on in each cell, one cell at a time.

    With single-cell sequencing of 614,000 cells, the team saw the brain's immune cells change most. [20]

    Seen it before

    A class photo shows the group, but asking each pupil shows who is actually unwell.

    The truth

    • The gene readings came from just 7 Alzheimer's patients, 7 healthy people and 3 younger donors. [20]
  10. 12

    Brain immune cells link genes to dementia

    What happened

    • Sanger Institute researchers grew brain immune cells from 261 lines of human stem cells to test dementia-risk genes. [21]
    • The team found 79 overlaps between gene activity and risk regions for 4 brain diseases. [21]
    • Half of those had little earlier evidence of causing disease. [21]
    • The study appeared in Nature Genetics. [21]

    Who is involved

    The cells, microglia, move around the brain clearing debris and misfolded proteins. [21]

    How it unfolded

    Gene surveys had found many DNA differences linked to disease without saying what they do. [21]

    Why it matters

    Drugmakers need to know which gene to hit, and in which cell, before designing a targeted medicine. [21]

    Think it through

    1. 1

      Why grow cells instead of studying brains?

      Living microglia are almost impossible to reach in people, the authors wrote. [21]

    2. 2

      What surprised them?

      The same gene change could have the opposite effect in a different cell setting. [21]

    How it works

    Geneticists call it a CRISPR screen: edit genes one by one in many cells and watch what changes.

    The CRISPR screen in microglia showed how a gene changed the cells' ability to move and clear debris. [21]

    Seen it before

    Flicking each switch in a house one at a time shows which one works the porch light.

    The truth

    • The microglia were made from stem cells in the lab, not taken from living brains. [21]
  11. 13

    A rare fever disease's cause rethought

    What happened

    • Garvan Institute researchers in Australia found a rare inherited disease, MKD, is driven by misfiring immune cells. [22]
    • MKD causes repeated attacks of high fever, rashes, joint pain and inflammation, sometimes deadly. [22]
    • About half of patients do not respond well to current drugs. [22]
    • The study found natural killer cells cannot release their poison, so they flood the body with alarm signals. [22]
    • One severely ill baby improved after doctors added baricitinib, an existing arthritis and eczema drug. [22]
    • The study appeared in the journal Immunity. [22]

    How it unfolded

    For 30 years, research and treatment focused on another immune cell, the macrophage. [22]

    Why it matters

    Patients who get no help from today's drugs may have a new target to try. [22]

    Think it through

    1. 1

      Why would weak killer cells cause too much inflammation?

      When they fail to kill infected cells, they pump out interferon gamma, a strong alarm signal. [22]

    2. 2

      Can a drug already on sale help?

      Baricitinib blocks the pathway interferon gamma uses, and it is already used for other illnesses. [22]

    How it works

    Immunologists call these natural killer cells: they destroy infected cells by releasing toxic granules.

    In MKD, the natural killer cells' granules stay trapped inside, so the cells shout for help instead. [22]

    Seen it before

    A guard who cannot open the door keeps ringing the alarm, and the whole building panics.

    The idea, in story 02: Why the protein that starts Alzheimer's may not be the one doing the damage →

    The truth

    • The drug result rests on 1 baby, which cannot show it works for others, the researchers say. [22]

    Good news

    • The baby's flare-ups came less often, and gut inflammation began to heal. [22]
  12. 14

    A receptor shields bowel cancer, in mice

    What happened

    • A study found colorectal cancer resists immunotherapy partly through FOLR1, a receptor that takes in folate. [23]
    • Only 15% of colorectal patients benefit a lot from anti-PD-1 drugs, a kind of immunotherapy. [23]
    • High FOLR1 predicted a poor response and worse outcomes. [23]
    • In mice, an approved drug, mirvetuximab soravtansine, blocked FOLR1 and restored the immunotherapy's effect. [23]

    How it unfolded

    Colorectal cancer is the 3rd most common cancer worldwide. [23]

    Why it matters

    The authors say adding FOLR1 drugs could help patients whose tumours resist immunotherapy. [23]

    Think it through

    1. 1

      How does the receptor hide the cancer?

      FOLR1 weakens a signal that helps tumour cells show markers to killer T cells. [23]

    2. 2

      Is it ready for patients?

      No: the result is in mice, and the authors call it only a clinically actionable approach. [23]

    How it works

    Immunologists call these drugs checkpoint blockers: they lift a brake cancer uses to switch off killer T cells.

    Here the checkpoint blocker anti-PD-1 failed in mice until mirvetuximab removed FOLR1's effect. [23]

    Seen it before

    Releasing a car's handbrake does nothing if the engine is still switched off.

    The truth

    • The evidence comes from mice and lab cells only. [23]
  13. 15

    Online health tests make baseless claims

    What happened

    • A UK study of 50 health tests sold online found many made claims without evidence. [24]
    • Researchers at the University of St Andrews published it in the journal BMJ Open. [24]
    • Prices ran from £6.99 for a home kidney test to £14,000 for a platinum assessment. [24]
    • 16 tests claimed, without evidence, that they could help people live longer. [24]
    • Only 15 explained the downsides of testing, such as inaccurate results. [24]
    • On Wednesday, the UK advertising watchdog upheld a ban on Voy's home testosterone test adverts. [24]

    Why it matters

    Wrong results can mean false alarms or false reassurance, the researchers warned. [24]

    Think it through

    1. 1

      Who checks these tests?

      Few cases ever reach regulators, which the researchers call a gap in regulation. [24]

    2. 2

      Why was Voy's advert banned?

      It linked tiredness and irritability to low testosterone to sell kits, the watchdog said. [24]

    How it works

    Public health doctors judge screening by its harms too: false alarms and false reassurance in healthy people.

    Of the 50 tests, only 15 mentioned those screening harms, while 36 promised earlier diagnosis. [24]

    Seen it before

    A smoke alarm that goes off at toast, or stays silent in a fire, does more harm than good.

    The truth

    • The study looked at 50 adverts, a sample of what is sold, not the whole market. [24]
  14. 16

    Boy behind Northern Ireland's organ law runs out

    What happened

    • Dáithí Mac Gabhann, 10, walked out as a mascot at Ireland's 3-0 win over Kosovo on Tuesday. [25]
    • He got a new heart in July after waiting 8 years. [25]
    • Under it, people become organ donors automatically unless they say they do not want to. [25]
    • A couple of years ago he needed a wheelchair to go out as a mascot. [25]

    How it unfolded

    He was born in 2016 with the left side of his heart not properly formed. [25]

    His family campaigned for Dáithí's Law, which began in Northern Ireland in 2023. [25]

    Why it matters

    The law changes the starting choice for everyone in Northern Ireland, not only for families like his. [25]

    Think it through

    1. 1

      What did the new heart change?

      He skipped out, sang loudly and was not out of breath once, his father said. [25]

    2. 2

      So who decides if someone donates?

      Each person still does: anyone can say no, but saying nothing now counts as yes. [25]

    How it works

    Behavioural economists call it a default: the choice that holds if nobody acts, which most people keep.

    Dáithí's Law made donating the default in Northern Ireland, so people who never act are counted as donors. [25]

    Seen it before

    Most people keep their phone's factory settings, whatever they are.

    The truth

    • The report gives no figures on donations since 2023, which decides whether the new default worked. [25]

    Good news

    • After 8 years of waiting, he got a heart and is living life to the fullest, his father said. [25]
  15. 17

    A cortisol pill slows dementia in over-75s

    What happened

    • Actinogen, an Australian biotech, said its daily pill Xanamem slowed Alzheimer's by 30% in patients over 75. [27]
    • The trial gave 247 people with mild to moderate Alzheimer's, in Australia and the US, 36 weeks of treatment. [27]
    • Across the whole trial, the pill showed no statistically significant benefit. [27]
    • The over-75s were half the trial: everyone above its median age of 75. [27]
    • The pill blocks production of cortisol, a stress hormone, in brain areas tied to the disease. [27]

    Who is involved

    • Donanemab and lecanemab clear amyloid
    • Xanamem lowers cortisol

    How it unfolded

    The approved antibody drugs, donanemab and lecanemab, instead clear amyloid plaque from the brain. [27]

    Why it matters

    Actinogen's chief Steven Gourlay said: "Nobody's really developing anything for the older patients". [27]

    Think it through

    1. 1

      Is 30% as good as the approved drugs?

      Not shown: its chief compares it with 22% to 27% for antibody drugs, but those came from other trials. [27]

    2. 2

      Why might it work only in older patients?

      Older patients have more signs of brain inflammation, and the pill may lower it, Actinogen's chief says. [27]

    3. 3

      So what decides where it goes next?

      A Dementia Australia adviser, Michael Woodward, says the result could help shape the next phase of trials. [27]

    How it works

    Endocrinologists say cortisol, a hormone the body needs, can harm cells when it stays high for a long time.

    Xanamem tests that endocrine idea: long-high cortisol may poison nerve cells, so the pill lowers it in the brain. [27]

    Seen it before

    Sunlight feeds a plant, but a lamp left on all night can scorch its leaves.

    The truth

    • The 30% comes from one half of the trial, while the trial as a whole showed no clear benefit. [27]
  16. 18

    Pennsylvania counts an 8th measles death

    What happened

    • An unvaccinated Pennsylvania resident died of measles, the state's 8th measles death this year. [28]
    • The Pennsylvania Department of Health confirmed the death on Wednesday; the person lived in Clinton County. [28]
    • Pennsylvania has reported 1,589 cases in 46 of its 67 counties. [28]
    • The CDC had counted 5,412 US cases this year as of 12 November. [28]
    • State staff have given more than 11,500 MMR vaccine doses this year, 7,200 of them at pop-up clinics. [28]

    How it unfolded

    The death came days after the US lost its measles elimination status, held for nearly 26 years. [28]

    1. Tuesday elimination status lost
    2. Wednesday 8th Pennsylvania death confirmed

    Why it matters

    About 90% of people who are not immune catch measles when exposed, so unvaccinated people carry the risk. [28]

    Think it through

    1. 1

      What does the US health secretary say now?

      Robert Kennedy Jr, who has questioned the MMR vaccine, recommended it on Tuesday after the status was lost. [28]

    2. 2

      So what actually stops the outbreak?

      Vaccination does, not the elimination label, says CDC director Erica Schwartz. [28]

    How it works

    Epidemiologists call measles eliminated when no single strain keeps spreading in a country for 12 months or more. [28]

    PAHO, the WHO's arm for the Americas, reviewed US spread data and ended its elimination status on Tuesday. [28]

    Seen it before

    A school is called lice-free only after a full term with no new case, not after one clean week.

    The truth

    • The CDC's latest national count, 5,412 cases, runs only to 12 November, before this death. [28]
  17. 19

    A pancreatic cancer drug starts a new trial

    What happened

    • Amplia Therapeutics, a biotech company, won ethics approval to test narmafotinib with chemotherapy in advanced pancreatic cancer. [29]
    • The ACCENT-Mini trial will test a daily dose at 3 Australian sites to find the best safe dose. [29]

    How it unfolded

    In an earlier trial, ACCENT, tumours shrank in 36% of patients given the drug with chemotherapy. [29]

    Patients in that trial lived a median of 11.1 months. [29]

    1. Now ACCENT-Mini starts
    2. Early 2027 results, then FDA plan

    Why it matters

    Patients with metastatic pancreatic cancer have few options, Amplia's chief Chris Burns says. [29]

    Think it through

    1. 1

      How is it meant to help chemotherapy?

      Amplia says blocking FAK, a protein that builds scar-like walls round tumours, lets chemotherapy reach the cancer. [29]

    2. 2

      Who else is in this race?

      The FDA recently approved a drug aimed at KRAS, a gene changed in over 90% of pancreatic cancers. [29]

      90 of 100

      pancreatic cancers with a KRAS change, at least

    How it works

    Oncologists call it combination therapy: one drug breaks a tumour's defence so another can do the killing.

    In this combination therapy, narmafotinib targets the tumour's fibrous wall while gemcitabine and Abraxane attack the cancer cells. [29]

    Seen it before

    A gardener cuts back thick weeds so the spray can reach the roots.

    The truth

    • The new trial tests safety and dose, not whether patients live longer. [29]

    What comes next

    Amplia will use the results, due in early 2027, to plan a larger trial with the FDA. [29]

Across the beats